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CASE REPORT
Secondary leukemia occurring after hematopoietic stem cell transplantation (HSCT) for acute myeloid leukemia
(AML) is rare. Secondary AML usually follows autologous and not allogeneic transplants. When a new leukemia
develops in a patient successfully treated with an allogeneic HSCT, the possibility of a de novo or secondary
leukemia from either the donor or recipient should be considered. We present a case initially diagnosed as de
novo AML without a cytogenetic abnormality. The patient was successfully treated with an HLA-matched sibling
allogeneic HSCT. However, more than six years later, AML developed again and was associated with new
complex cytogenetic abnormalities. After a second HSCT, the patient has been followed without serious
complications. Considering the allogeneic setting, the newly developed cytogenetic abnormalities, a relatively long
latent period, and the good clinical course after the second allogeneic HSCT, this case might represent a second
de novo AML following successful treatment of the first AML. (Korean J Intern Med 2010;25:110-113)
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INTRODUCTION
Secondary leukemia or de novo leukemia should be
considered when a new leukemia develops after successful
treatment of various malignancies. Secondary leukemia
refers to the appearance of a new, biologically-unrelated
leukemia different from the primary malignancy,
following the treatment of the primary malignancy; de
novo leukemia refers to leukemia in patients without
exposure to potentially leukemogenic therapies or agents.
In patients that undergo allogeneic hematopoietic stem
cell transplantation (HSCT), the possibility of the
appearance of leukemia from allogeneic hematopoiesis
(donor cell leukemia) as well as de novo or secondary
leukemia, which originates in the recipient, should also be
considered despite lower likelihood and difficulty to
confirm. It is not surprising that a large percentage of
patients who develop secondary acute myeloid leukemia
(AML) were previously treated for hematological disorders
but not solid tumors, considering the responsiveness of
hematologic malignancies to chemotherapy [1]. However,
in most cases, prior treatment was not for leukemia but
for lymphoma and myeloma [2,3]. Indeed, although
malignancies after HSCT has been well documented [4],
secondary leukemia occurring after HSCT for AML is rare
[5,6]. In addition, most reports of secondary AML follow
autologous transplantation, and it is rare following allogeneic
transplantation regardless of the primary disease [4],
primarily because the anti-leukemic effects of the allogeneic
graft reduce the risk of a secondary clone developing.  
We present a case initially diagnosed as a de novo
AML without a cytogenetic abnormality. The patient wasCho BS, et al. Acute myeloid leukemia after transplantation    111
successfully treated with a HLA-matched sibling allogeneic
HSCT. However, more than six years later, a second AML
developed that was associated with new complex cytogenetic
abnormalities. 
CASE REPORT
A 36-year-old man was diagnosed with AML-M1 by the
FAB classification in April 1998 (Fig. 1A). His chromosome
analysis showed a 46, XY karyotype without any cytogenetic
abnormalities (Fig. 2A). He was treated with induction
chemotherapy (idarubicin 12 mg/m2/d on days 1 to 3,
enocitabine 300 mg/m2/d on days 1 to 7, 6-thioguanine
100 mg/m2, bid on days 1 to 7) and augmentation
chemotherapy (enocitabine 400 mg/m2/d for 2 days). He
achieved a complete remission, and underwent consolidation
chemotherapy with amsacrine 100 mg/m2/d on days 1 to 3
and etoposide 100 mg/m2/d on days 1 to 5. The patient
had two HLA-identical sisters out of his three siblings, and
received an allogeneic bone marrow (BM) HSCT from one
of his fully matched sisters on December 1998; conditioning
included fractionated total body irradiation (TBI) 1200
cGy for three days, followed by cyclophosphamide 120
mg/m2 for two days. On day 21, a BM biopsy revealed
morphologically stable engraftment with definite three-
lineage maturation. The first HSCT resulted in a
continuous, complete remission that lasted seventy three
months. On December 2004, he presented with a
hemoglobin of 9.1 g/dL, white blood cells 2.0 × 109/L and
platelets 52 × 109/L. A BM aspirate showed that a majority
of the nucleated elements were blasts without dysplastic
changes (Fig. 1B). Cytogenetic analysis showed a complex
karyotype: 46,X, der(Y)t(Y;15)(q11.2;q11.2), del(1)(q32),
t(1;3)(p36.1;q21),inv(3)(p21q25),add(4)(p16),
del(7)(q22),+8,inv(9)(p13p24),-15,add(16)(p13.3)[8]/
46,idem,del(13)(q12q22)[3]/46,XX[9](Fig. 2B). Molecular
analysis with a Y-chromosome probe revealed that the
abnormal chromosomes originated from the recipient.
The patient achieved morphological and cytogenetic
remission again with reinduction chemotherapy; he
underwent a second allogeneic peripheral blood HSCT
from another human leukocyte antigen-identical sister on
May 2005. Stable engraftment and normal peripheral
blood counts were achieved. The patient has been followed
for over 12 months after the second HSCT without serious
complications.
DISCUSSION
This case is characterized by a longer latency period
than in previous reports of secondary AML following
hematologic and/or non hematologic malignancies [2,3]
as well as rare cases of secondary AML following de novo
AML [5,6], in the setting of an allograft. In our case, the
new complex cytogenetic aberrations, as well as the
allograft setting, suggested that the origin of the second
AML might be biologically unrelated to the first. There are
two possible origins for the second AML: a secondary AML,
Figure 1. Light microscopic findings of the bone marrow aspirate. (A) The first diagnosed acute myeloid leukemia (AML). There are
myeloblasts showing small-to medium-sized, round to oval nuclei with fine chromatin, prominent nucleoli, and a small to moderate
amount of blue cytoplasm (64% of all nucleated elements, Wright and Giemsa stain, ×1,000). (B) The second diagnosed AML. Thirty
percent of all nucleated elements were myeloblasts (Wright and Giemsa stain, ×1,000).
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another de novo AML, or perhaps a donor cell leukemia.
Secondary AML is primarily associated with therapy-
related myelodysplasia and/or therapy-related AML (t-
AML) as a late complication following cytotoxic therapy
[1-3,5,6]. t-AML consists of 2 different syndromes: one
with a long latency (5 to 7 years or more) observed following
the administration of alkylating agents, which frequently
show antecedent dysplastic changes and clonal abnor-
malities with loss of all or part of chromosome 5 or 7, or
both. The other syndrome has a short latency period (1 to 3
years), with no antecedent dysplastic phase, abnormalities
of chromosome 11, specifically 11q23, or abnormalities of
chromosome 21q22, and usually follows the use of
topoisomerase II inhibitors [1]. Our patient received
topoisomerase II inhibitors for induction (idarubicin) and
consolidation (amsacrine and etoposide) chemotherapy,
and the alkylating agents, TBI/cyclophosphamide, for
conditioning therapy. In our case, the long latency period
and cytogenetic abnormalities characterized by deletion of
7q would suggest that the newly developed AML might be
a t-AML caused by cyclophosphamide and/or TBI, rather
than by topoisomerase II inhibitors. However, the dose
of cyclophosphamide was much lower than normally
associated with t-AML [7], there were no antecedent
dysplastic changes and relatively long latency period, and
secondary AML is very rare in the allograft setting [4],
making it difficult to verify this possibility.
Another possibility is the development of another
primary AML, either de novo AML or donor cell leukemia.
However, donor cell leukemia was excluded by cytogenetic
studies showing the aberrations associated with a Y
chromosome. Then, is the second de novo AML of recipient
origin? First, our case had a longer latent period and an
allogeneic HSCT. Generally, in all grafted adult AML,
patients without a relapse or chronic graft-versus-host
disease five years after allogeneic HSCT are often
considered “cured”. Second, deletion of 7q, which may be
associated with alkylating agents, often occurs in de novo
AML as well as secondary AML [8]. Third, considering the
possible graft-versus-leukemia effect of the allograft, our
patient was probably cured and then developed a new
AML later. Finally, the patient showed a good clinical
course after the second allogeneic HSCT; secondary AML
due to alkylating agents has a uniformly poor prognosis
Figure 2. Cytogenetic analysis of bone marrow cells. (A) The first acute myeloid leukemia (AML) had a normal karyotype. The second
AML had a complex karyotype with (B) 46,X, der(Y)t(Y;15)(q11.2;q11.2),del(1)(q32),t(1;3)(p36.1;q21),inv(3)(p21q25),add(4)(p16),
del(7)(q22),+8,inv(9)(p13p24),-15,add(16)(p13.3)[8], (C) 46,idem,del(13)(q12q22)[3], and (D) 46,XX[9]. 
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[1]. Alternatively, the clones found in the second AML
may have been undetected subclones at the time of the
first AML that later gained proliferative potential after the
HSCT. However, this is unlikely and would be difficult to
prove even with molecular genetic analysis [5]. 
In conclusion, our patient may have had a second de
novo AML following successful treatment of the first de
novo AML, although we could not rule out other possibilities.
Future studies of a patient’s intrinsic genetic makeup may
help indicate a predisposition to the rare development of
a secondary or de novo AML. 
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